Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: The Cache County Study

International Journal of Geriatric Psychiatry

Volumn 29, Issue 2, 2014, Pages 153-159

  Steinberg, Martin ^a   Hess, Kyle ^b   Corcoran, Chris ^b   Mielke, Michelle M ^c   Norton, Maria ^b   Breitner, John ^d,g   Green, Robert ^e   Leoutsakos, Jeannie ^a   Welsh Bohmer, Kathleen ^f   Lyketsos, Constantine ^a   Tschanz, Joann ^b  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; dementia; neuropsychiatric; vascular

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

AGITATION; ALZHEIMER DISEASE; ANGINA PECTORIS; ANXIETY; APATHY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CORONARY ARTERY BYPASS SURGERY; DELUSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW UP; HALLUCINATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; IRRITABILITY; LOCOMOTION; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; PSYCHOSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ALZHEIMER'S DISEASE; DEMENTIA; NEUROPSYCHIATRIC; VASCULAR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 84892443211     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3980     Document Type: Article

References (50)

1. Arbus C, Gardette V, Cantet CE, et al,. REAL.FR Group. 2011. Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study. J Nutr Health Aging 15: 609-617.
2. Archer N, Brown RG, Reeves SJ, et al,. 2007. Premorbid personality and behavioral and psychological symptoms in probable Alzheimer's disease. Am J Geriatr Psychiatry 15: 202-213.
3. Banerjee S, Samsi, K, Petrie CD, et al,. 2009. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry 24: 15-24.
4. Banerjee S, Hellier J, Dewey M, et al,. 2011. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicenter, double-blind, placebo-controlled trial. Lancet 378: 403-411.
5. Bassiony MM, Steinberg M, Warren A, et al,. 2000. Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates. Int J Geriatr Psychiatry 15: 99-107. (Pubitemid 30125125)
6. Beeri MS, Werner P, Davidson M, Noy S,. 2002. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 17: 403-408.
7. Berlow YA, Wells YM, Ellison JM, et al,. 2010. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease. Int J Geriatr Psychiatry 25: 780-788.
8. Black BS, Johnston D, Morrison A, et al,. 2012. Quality of life of community-residing persons with dementia based on self-rated and caregiver-rated measures. Qual Life Res 21: 1379-1389.
9. Boyle PA, Malloy PF,. 2004. Treating apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 17: 91-99. (Pubitemid 37499972)
10. Breitner JC, Wyse BW, Anthony JC, et al,. 1999. APOE-epsilon 4 count predicts age when prevalence of Alzheimer's disease increases, then declines: the Cache County Study. Neurology 53: 321-331. (Pubitemid 29344354)
11. Casanova MF, Starkstein SE, Jellinger KA,. 2011. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropath 122: 117-135.
12. Copeland MP, Daly E, Hines V, et al,. 2003. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord 17: 1-8. (Pubitemid 36288240)
13. Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP,. 2005. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 13: 460-468.
14. Cummings JL, Mega M, Gray K, et al,. 1994. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314. (Pubitemid 24382728)
15. Finklel S,. Introduction to behavioural and psychological symptoms of dementia (BPSD). 2000. Int J Geriatr Psychiatry 15 (Suppl 1): S2-4.
16. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
17. Gill SS, Bronskill SE, Normand SL, et al,. 2007. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146: 775-86. (Pubitemid 351650498)
18. Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC,. 1999. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 14: 701-710. (Pubitemid 29450281)
19. Harwood DG, Barker WW, Ownby RL, Duara R,. 1999. Prevalence and correlates of Capgras syndrome in Alzheimer's disease. Int J Geriatr Psychiatry 6: 415-420. (Pubitemid 29286844)
20. Harwood DG, Barker WW, Ownby RL, Duara R,. 2000. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease. Int J Geriatr Psychiatry 15: 393-400. (Pubitemid 30325790)
21. Holtzer R, Tang MX, Devanand DP, et al,. 2003. Psychopathological features in Alzheimer's disease: course and relationship with cognitive status. J Am Geriatr Soc 51: 953-960. (Pubitemid 36871143)
22. Jeste DV, Blazer D, Casey D, et al,. 2008. ANCP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharm 33: 957-970. (Pubitemid 351367549)
23. Kales HC, Valenstein M, Kim HM, et al,. 2007. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164: 1568-1576. (Pubitemid 350069737)
24. Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ,. 1994. A validation study of the Dementia Questionnaire. Arch Neurol 51: 901-906. (Pubitemid 24286045)
25. Lyketsos C, Steinberg M, Tschanz JT, et al,. 2000. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157: 708-14. (Pubitemid 30249648)
26. Lyketsos CG, Sheppard JM, Steinberg M, et al,. 2001. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 16: 1043-1053. (Pubitemid 33089268)
27. Lyketsos CG, DelCampo L, Steinberg M, et al,. 2003. Treating depression in Alzheimer's disease: efficacy and safety of sertraline therapy and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 7: 737-746. (Pubitemid 36818637)
28. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944. (Pubitemid 14076461)
29. Mielke MM, Rosenberg PB, Tschanz J, et al,. 2007. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850-1858. (Pubitemid 350071146)
30. Mizrahi R, Starkstein SE, Jorge R, Robinson RG,. 2006. Phenomenology and clinical correlates of delusions in Alzheimer's disease. Am J Geriatr Psychiatry 14: 573-581. (Pubitemid 44036481)
31. O'Brien J, Perry R, Barber R, Gholkar A, Thomas A,. 2000. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann NY Acad Sci 903: 482-489. (Pubitemid 30251593)
32. Palmer K, Lupo F, Perri R, et al,. 2011. Predicting disease progression in Alzheimer's disease: the role of neuropsychiatric syndromes on functional and cognitive decline. J Alzheimers Dis 24: 35-45.
33. Palmqvist S, Sarwari A, Wattmo C, et al,. 2011. Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 33: 417-423.
34. Paulsen JS, Salmon DP, Thal LJ, et al,. 2000. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 54: 1965-1971. (Pubitemid 30327121)
35. Rabins PV, Lyketsos CG, Steele CD,. 1999. Practical Dementia Care. New York, Oxford University Press.
36. Rao V, Spiro JR, Rosenberg PB, et al,. 2006. An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD). Int J Geriatr Psychiatry 21: 273-274.
37. Rosenberg PB, Mielke MM, Han D, et al,. 2012. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry Epub ahead of print
38. Schneider LS, Tariot PN, Dagerman KS, et al,. CATIE-AD Study Group. 2006. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355: 1525-1538. (Pubitemid 44547805)
39. Sink KM, Holden KF, Yaffe K,. 2005. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293: 596-608. (Pubitemid 40171242)
40. Starkstein SE, Petracca G, Chemerinski E, Kremer J,. 2001. Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 158: 872-877. (Pubitemid 32547615)
41. Starkstein SE, Jorge R, Mizrahi R, Robinson RG,. 2006. A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 77: 8-11. (Pubitemid 43022682)
42. Steinberg M, Shao H, Zandi P, et al,. Cache County Investigators. 2008. Point and five-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23: 170-177. (Pubitemid 351308497)
43. Tariot PN, Mack JL, Patterson MB, et al,. 1995. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 152: 1349-1357.
44. Treiber KA, Lyketsos CG, Corcoran C, et al,. 2008. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. Int Psychogeriatr 20: 538-553. (Pubitemid 351465551)
45. Truelsen T, Lindenstrom E, Boysen G,. 1994. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke 25: 802-807. (Pubitemid 24111327)
46. Tsai SJ, Hwang JP, Yang CH, Liu KM,. 1996. Physical aggression and associated factors in probable Alzheimer's disease. Azheimer Dis Assoc Disord 10: 82-85.
47. Tschanz JT, Welsh-Bohmer KA, Plassman BL, et al,. The Cache County Study Group. 2002. An adaptation of the Modified Mini-Mental State Examination: analysis of demographic influences and normative date: the Cache County Study. Neuropsychiatry Neuropsychol Behav Neurol 15: 28-38. (Pubitemid 34213814)
48. Tschanz JT, Corcoran CD, Schwartz S, et al,. 2011. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer's disease: the Cache County Dementia Progression study. Am J Geriatr Psychiatry 19: 532-542.
49. Verbeek DE, van Riezen J, de Boer RA, van Melle JP, de Jonge P,. 2011. A review of the putative association between beta-blockers and depression. Heart Fail Clin 7: 89-99.
50. Weintraub D, Rosenberg PB, Drye LT, et al,. DIADS-2 Research Group. 2010. Sertraline for the treatment of depression in Alzheimer disease: week 24 outcomes. Am J Geriatr Psychiatry 18: 332-340.